iiCON at the heart of infectious disease research This year, a new AI robotic laboratory designed to accelerate the discovery of drugs and vaccines for infectious diseases was announced in Liverpool UK. The £20 million ($26.4 million) Liverpool Accelerate Laboratory was developed through the Infection Innovation Consortium: iiCON – an initiative dedicated… Read More
In this paid-for advertorial for the Fall 2026 issue of DDW, Sampled shares insight on neurological disease with a genomics and multiomics lens. Genomic testing can identify drivers of neurological disease, but many variants remain difficult to interpret. Multiomics helps to close this gap by connecting genetic findings with… Read More
In his editorial comment for the Fall 2026 issue of DDW, Editor Reece Armstrong discusses innovation, investment, and how these come together in the Drug Discovery Innovators & Investors (DDII) event series. In my time with DDW, I’ve learned first-hand about the challenges drug discovery and development… Read More
In this series, DDW speaks to women in leading positions across biopharma about the work they’re doing and their experiences within the industry. Here, we speak to Charlotte Edenius, Gesynta, co-founder and VP of R&D Strategy of Gesynta Pharma about the company’s approach to treating pain and inflammation and… Read More
Stacey Willard, Vice President of Marketing and Product Management at Nuclera, explores the validation bottleneck for antibody engineering and why generative AI may be the answer to this challenge. Antibody engineering has developed a pronounced asymmetry. AI can now generate and rank antibody candidates at a pace that conventional experimental… Read More
Dr James Heward, VP Functional Genomics at Nucleome Therapeutics, discusses what could be the missing link in the chain of causality from patient to target to drug. The fundamental question that stalks every drug discovery project is “will this drug fail?” Most do. There is no single reason for more than 90% of clinical… Read More
DDW Editor Reece Armstrong speaks to Dr Carlos Buesa, Founder and CEO of Oryzon Genomics, about epigenetic approaches to treating cancer and the company’s current journey within drug discovery and development. RA: Can an epigenetic approach help tackle aggressive cancers and those with poor prognoses? CB: Yes. Many aggressive cancers are… Read More
Jack O’Meara CEO and Co-Founder of Aerska, compares the cardiovascular field to advances in neuroscience and how a preventative approach could be on the horizon for diseases such as Alzheimer’s. At Ochre Bio, the company I ran before Aerska, we spent years keeping human livers alive outside the body. Organs turned down for transplant, hooked up to… Read More
Racura Oncology recently raised AU$34.3 (US$24.31) million to fund its RC220 clinical programmes in acute myeloid leukaemia (AML), epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer, and anthracycline cardioprotection in solid tumour patients. Diana Turner speaks to Dr Peter Smith, Executive Chair of Racura, about… Read More
In June 2026, China’s National Medical Products Administration cleared satricabtagene autoleucel (satri-cel), CARsgen’s Claudin18.2 CAR-T, for advanced gastric cancer. It became the world’s first CAR-T cell therapy approved for a solid tumour. The science is genuinely impressive. But the geography is the story. Satri-cel is not a Chinese… Read More
Daniel Delubac, Chief Executive Officer at iOrganBio looks at how technologies that mimic human behaviour can improve drug discovery efforts past animal models. The US is signalling a decisive shift toward human-based drug discovery. In March, the National Institutes… Read More
Nigel Brooksby, Executive Chair at AMR Bio reinforces the warnings about antimicrobial resistance (AMR) and highlights that the threat isn’t being taken seriously enough. Antimicrobial resistance has become a familiar threat that has bred complacency There is no shortage of evidence to show that antimicrobial resistance is one of the greatest long-term threats to global health. The scientific consensus continues… Read More
Darren Heywood, Senior Product Manager at Promega UK, examines assay formats built specifically for 3D measurements. A 3D microtissue, such as a spheroid or organoid, is not a monolayer with more cells. These are three-dimensional… Read More
Kelsey Jakee, Senior Director, Portfolio Strategy & Innovation at TransCelerate BioPharma, argues why advances in clinical R&D won’t solely be dependent on technology. Every… Read More
Daniel Delubac, Chief Executive Officer at iOrganBio, looks at how technologies that mimic human behaviour can improve drug discovery efforts past animal models. The US is signalling a decisive shift toward human-based drug discovery. In March, the National Institutes of Health… Read More
Partha Anbil, SVP, Life Sciences, at Coforge Limited, and Alex Kandybin, Founder of Quantum Wargaming, explore how quantum computing is… Read More
